Vaccine疫苗
Vaccine(英文缩写 VACCINE),ISSN 0264-410X,eISSN 1873-2518,中文译名:疫苗 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-01 至 2026-08-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 4.169 | Q3 |
| 2022 | 5.500 | Q2 |
| 2023 | 4.500 | Q2 |
| 2024 | 3.500 | Q2 |
| 2025 | 3.400 | Q2 |
Vaccine 最新收录文献
-
1. A leap forward in vaccination - a molecular process of epigenetic silencing to the virus.
PMID:日期:2026-10-03Immunization is a procedure that trains and strengthens host immunity against harmful foreign agents from damaging and even taking the life of the host. Immunization or vaccination has opened the era of modern medicine, contributed to independence, health, and prosperity of the nation. Resonating with current USA scientific progress, vaccinology needs to take an appropriate leap forward. The review traces the history of vaccine development in USA, recaps multidiscipline-nary research more than four-decade on acquired immunodeficiency syndrome (AIDS), appeals to generating a next-generation vaccine - chromatin vaccine and elicits the newly defined host immunity - epigenetic immunity for a cure.
-
2. Evaluating the influence of vaccine archetypes and epidemiological conditions on clinical trial metrics for tuberculosis vaccine candidates.
PMID:日期:2026-10-03Conducting tuberculosis vaccine trials in high-transmission settings offers potential gains in efficiency, yet the impact of repeated exposure in the presence of incomplete protection on measured vaccine efficacy is uncertain. We evaluated the effect of vaccine characteristics and epidemiological context on estimates of vaccine efficacy and requisite sample size for tuberculosis vaccine trials. We simulated clinical trials of hypothetical tuberculosis vaccines using a stochastic compartmental model of tuberculosis natural history. We considered vaccines that confer "leaky" (50% per-exposure reduction) versus "all-or-none" protection against infection and/or disease that were evaluated in QuantiFERON Gold Plus (QFT) positive, negative or mixed populations with 2% (medium burden; incidence 400 per 100,000), 5% (high burden; 800 per 100,000) or 50% (very high burden; 4500 per 100,000) annual risk of infection (ARI), including protection against infection alone. We compared estimates of vaccine efficacy and statistical power to detect differences according to sample size for each vaccine archetype and epidemiologic setting. Simulated trials of vaccines protecting against disease, alone or with protection against infection, gave comparable estimates of efficacy across epidemiological settings, whether all-or-none or leaky. The largest reduction was for a leaky vaccine protecting against both infection and disease in QFT negative participants, whose efficacy fell from 75% at medium ARI to 67% at very high ARI (relative reduction 11%). A vaccine acting only by preventing infection fell further, from 50% to 36% (28%). Trials at very high ARI could nonetheless achieve 90% power with 80-96% fewer participants than at medium ARI. While vaccines conferring leaky protection against infection and disease tested in settings with very high ARI could modestly underestimate efficacy, trials could be adequately powered with a fraction of the sample size in such settings. Further, trials could enroll a mixture of QFT negative and positive individuals, increasing generalizability.
-
3. A recombinant attenuated PRRSV vaccine expressing the PCV2 capsid protein confers protective immunity in pigs.
PMID:日期:2026-10-03Porcine reproductive and respiratory syndrome virus (PRRSV) and porcine circovirus type 2 (PCV2) are major swine pathogens that cause severe disease and frequently occur as coinfections in pig herds. Current vaccination strategies against PRRSV and PCV2 commonly rely on separate vaccines, which may increase the complexity of immunization programs and require repeated animal handling. Therefore, a bivalent vaccine platform capable of inducing immune responses against both pathogens would be valuable for simplifying vaccination strategies. In this study, the attenuated PRRSV strain HuN4-F112 was used as a live viral vector to express the PCV2d capsid (Cap) protein. The recombinant virus rHuN4-F112-Cap was successfully rescued using a reverse-genetics system. rHuN4-F112-Cap showed growth characteristics comparable to those of the parental HuN4-F112 strain in MARC-145 cells, and expression of the inserted PCV2 Cap gene was confirmed. A single intramuscular immunization with rHuN4-F112-Cap induced PRRSV and PCV2 specific antibody responses in piglets, as well as PCV2-neutralizing antibodies before challenge. In separate challenge models, vaccinated piglets showed reduced PCV2 DNA loads and milder lymphoid lesions after PCV2 challenge, and reduced clinical signs, lower PRRSV RNA loads, milder pulmonary lesions, and improved survival after highly pathogenic PRRSV challenge compared with DMEM-inoculated controls. These findings indicate that rHuN4-F112-Cap has potential as a bivalent live-vector vaccine candidate against PRRSV and PCV2.
-
4. An immunoinformatics-based multi-epitope vaccine candidate confers cross-protection against two Actinobacillus pleuropneumoniae serovars.
4. 一种基于免疫信息学的多表位候选疫苗对两种胸膜肺炎放线杆菌血清型具有交叉保护作用PMID:日期:2026-10-03Porcine contagious pleuropneumonia (PCP) is caused by Actinobacillus pleuropneumoniae (APP) and inflicts heavy economic losses on the swine industry. However, existing inactivated vaccines provide limited cross-protection, highlighting the need for improved vaccine strategies. In this study, we combined pangenome analysis with subtractive proteomics to screen the APP core genome and identified 11 potential antigens. Seven of them showed immunoreactivity by ELISA and Western blotting. These antigens, together with the ApxI-III toxins, were used for T and B cell epitope prediction. On this basis, a multi-epitope fusion protein MVAPP was constructed. In silico molecular docking with swine immune receptors and immune simulations suggested that MVAPP has the potential to induce immune responses. In the mouse model, that MVAPP elicited specific antibody responses, shifted the splenic T-cell subset distribution toward CD4 T cells, and provided partial protection against challenge with strains from two serovars. In conclusion, MVAPP represents a potential multi-epitope vaccine candidate for further development against APP.
-
5. Ethical considerations of incentive structures in vaccine acceptance research.
PMID:日期:2026-10-03该文献暂无摘要。
-
6. Evaluating the potential lifetime health and economic impact of PCV21, an adult-specific 21-valent pneumococcal conjugate vaccine, on invasive pneumococcal disease in adults aged ≥45 years in Spain.
PMID:日期:2026-10-03PCV21, a 21-valent pneumococcal conjugate vaccine (PCV), includes eight unique serotypes not covered by other currently licensed pneumococcal vaccines, and accounts for approximately 79% of IPD cases among adults aged ≥65 years in Spain, compared with 65% for PCV20. This study evaluated the potential lifetime health and economic impact of PCV21 compared with PCV20 vaccination on IPD among adults aged ≥45 years in Spain. A published Markov model estimated the lifetime IPD cases, IPD-related deaths, and associated direct medical costs (2024 Euros) for Spanish adults aged 45-64 and ≥ 65 years vaccinated with either PCV21 or PCV20. A sensitivity analysis assessed the effect of varying inputs on the direct costs averted by PCV21 compared with PCV20. For adults aged 45-64 years, PCV21 was projected to prevent 1590 IPD cases and 134 IPD-related deaths, compared with 1412 cases and 114 deaths prevented with PCV20. Compared with PCV20, PCV21 averted 13% more IPD cases and 17% more IPD-related deaths. The greater reduction in IPD burden translated into €7.3 million in direct medical costs saved with PCV21, 10% higher than the €6.6 million saved with PCV20. Among adults aged ≥65 years, PCV21 was projected to prevent 10,262 IPD cases and 2207 IPD-related deaths, compared with 8243 cases and 1772 deaths prevented with PCV20. Compared with PCV20, PCV21 averted 24% more IPD cases and 25% more IPD-related deaths. The corresponding economic impact was also higher with PCV21, with €1301 million in direct medical costs saved compared with €1044 million for PCV20, representing a 25% greater reduction in costs. In both age groups, PCV21 showed greater health and economic impact associated with IPD compared with PCV20, underscoring the potential benefits of incorporating PCV21 into adult pneumococcal vaccination strategies in Spain.
-
8. Maternal vaccination with RSVpreF and risk of hypertensive disorders of pregnancy: a systematic review and meta-analysis.
PMID:日期:2026-10-03A bivalent respiratory syncytial virus (RSV) prefusion F protein-based vaccine (RSVpreF) was approved in the United States in August 2023 for use during pregnancy to prevent infant RSV-associated lower respiratory tract disease. The pivotal phase 3 trial identified a numerical imbalance in hypertensive disorders of pregnancy (HDP) that did not reach statistical significance; postmarketing observational studies have since reported inconsistent findings. We conducted a systematic review and meta-analysis to assess this association. We searched MEDLINE, Embase, CENTRAL, Scopus, ClinicalTrials.gov, and WHO ICTRP from inception to Jan 26, 2026, for randomized controlled trials (RCTs) and observational studies comparing HDP outcomes in RSVpreF-vaccinated versus unvaccinated or placebo-receiving pregnant individuals. Unadjusted risk ratios (RRs) were pooled using a random-effects model; adjusted estimates from observational studies were pooled separately by inverse variance methods. This study is registered with PROSPERO (CRD420251026835). Nine studies were included (3 RCTs, 6 retrospective cohort studies; n = 148,267). RSVpreF vaccination was associated with a small but statistically significant increase in overall HDP risk (RR 1·08, 95% CI 1·02-1·13; p = 0·004; I = 44%), driven by the observational studies group (1·08, 1·02-1·14; I = 61%); RCTs showed a directionally consistent but non-significant RR (1·12, 0·87-1·43; I = 0%). The association was attributable to gestational hypertension, with no significant association for preeclampsia/eclampsia. Maternal RSVpreF vaccination was associated with a small increase in HDP attributable to gestational hypertension and driven primarily by observational studies, in which residual confounding remains possible. The benefits of infant RSV prevention remain substantial, and these findings support continued postmarketing surveillance and informed shared decision-making.
-
9. A cohort study to assess the safety and coverage of COVID-19, influenza, and pertussis vaccine in Australian pregnant women.
PMID:日期:2026-10-03The study aimed to evaluate the safety and impact of maternal influenza, pertussis, COVID-19 vaccine on perinatal outcomes and identify determinants of uptake among pregnant women in South Australia. This retrospective cohort study included 19,098 pregnant women who delivered at the Women's and Children's Hospital in South Australia between 2020 to 2023. Cox proportional-hazards models estimated hazard ratios (HRs) for time-sensitive perinatal outcomes, and log-binomial models were used for time-independent outcomes. Poisson regression models were used to estimate adjusted prevalence ratios (aPRs) to identify factors influencing maternal vaccine uptake. Overall, 64.1% received influenza, 74.1% pertussis, and 29.5% received ≥1 COVID-19 dose during pregnancy. Maternal influenza, pertussis, and COVID-19 vaccination were not associated with increased risks of hypertensive disorders, chorioamnionitis, premature rupture of membranes, antepartum or postpartum haemorrhage, small-for-gestational-age, or low birthweight. Following maternal influenza vaccination, a 13% protective effect against preterm birth was observed, with similar reductions after pertussis (17% and nearly 50% fewer stillbirths) and COVID-19 vaccination (aHR 0.79, 95% CI 0.68-0.92). Both maternal influenza (aRR 0.94, 95% CI 0.91-0.98) and pertussis vaccination (aRR 0.89, 95% CI 0.86-0.92) were associated with a lower likelihood of experiencing at least one obstetric complication. A small increase in diagnosed gestational diabetes was observed among women vaccinated against influenza or pertussis. Neonatal outcomes were favourable, with lower rates of resuscitation, early-onset sepsis, and low Apgar scores among infants of vaccinated mothers. Younger, multiparous, unmarried, and First Nations women were less likely to be vaccinated, with lower uptake also observed among mothers whose infants were discharged to non-parental care. Findings reaffirm the safety and added benefits of maternal influenza, pertussis, and COVID-19 immunisation, and highlight persistent inequities in uptake that require targeted, culturally safe strategies to ensure equitable protection for all pregnant women and their infants.
-
10. Immunogenicity of type 2 novel oral poliovirus vaccine administered in outbreak response, Kenya 2023: an observational cohort study.
PMID:日期:2026-10-03In 2023, novel oral polio vaccine type 2 (nOPV2) was used to respond to an outbreak of circulating vaccine-derived poliovirus type 2 (cVDPV2) in Kenya. We assessed the immunogenicity of one and two doses of nOPV2 administered during outbreak response. An observational cohort study was conducted from October to December 2023 in Kitui and Tana River counties in Kenya. Children aged 6-59 months were enrolled. Two nOPV2 doses were administered. Dried blood spots (DBS) were collected at enrollment, four-weeks after the first nOPV2 dose, and two- and four-weeks after the second nOPV2 dose. The DBS cards were tested at the US Centers for Disease Control and Prevention (CDC), Atlanta for the presence of poliovirus neutralizing antibodies using microneutralization assays. The primary endpoint was cumulative immune response after two nOPV2 doses. Of the 475 participants followed in the study, 461 (97%) completed all study visits and were included in the analysis. Four weeks after two nOPV2 doses, a cumulative type 2 immune response was observed in 285 (62%; 95% CI 57-66) of 461 participants. After one nOPV2 dose, type 2 immune response was observed in 196 (43%, 95% CI 38-47) of 461 participants. Type 2 seropositivity (titers ≥1:8) increased from 19% at enrollment to 72% after two nOPV2 doses. The study demonstrated an immune response in 62% of the participants following two nOPV2 outbreak vaccination rounds. These findings suggest that two nOPV2 doses may be insufficient to achieve high population immunity during poliovirus type 2 outbreak response in sub-Saharan Africa.